Related Experiment Videos

Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention

    JAMA
    |September 24, 1982
    PubMed

    Insights

    The Multiple Risk Factor Intervention Trial found no significant difference in coronary heart disease (CHD) mortality between a special intervention group and usual care. Further investigation is needed to understand the complex effects of multifactor interventions on cardiovascular health.

    Area of Science:

    • Cardiovascular Disease Prevention
    • Clinical Trials
    • Public Health Interventions

    Background:

    • Coronary heart disease (CHD) remains a leading cause of mortality.
    • Primary prevention trials are crucial for evaluating interventions to reduce cardiovascular risk.
    • The Multiple Risk Factor Intervention Trial (MRFIT) aimed to assess a multifactor intervention's impact on high-risk men.

    Purpose of the Study:

    • To evaluate the effectiveness of a special intervention (SI) program compared to usual care (UC) in reducing CHD mortality.
    • To analyze the impact of multifactor risk reduction on cardiovascular outcomes in high-risk men.
    • To explore potential explanations for observed mortality rates in the trial.

    Main Methods:

    • A randomized primary prevention trial involving 12,866 high-risk men aged 35-57 years.
    • Participants were assigned to either a special intervention (SI) program or usual care (UC).
    • The SI program included hypertension treatment, smoking cessation counseling, and cholesterol-lowering dietary advice.

    Main Results:

    • Risk factor levels declined in both SI and UC groups, with greater reductions in the SI group.
    • CHD mortality was 17.9/1,000 in the SI group and 19.3/1,000 in the UC group (a nonsignificant 7.1% difference).
    • Total mortality rates were similar between groups (41.2/1,000 SI vs. 40.4/1,000 UC).

    Conclusions:

    • The multifactor intervention did not demonstrate a statistically significant reduction in CHD mortality over seven years.
    • Possible explanations include insufficient trial duration, lower-than-expected mortality, or offsetting effects of antihypertensive therapy.
    • Further research is needed to refine preventive strategies, particularly regarding the balance of different risk factor modifications.

    Related Concept Videos